Tacere Takes Back Asian Rights to HCV Program as It Waits on Pfizer
February 10, 2011
Tacere Takes Back Asian Rights to HCV Program as It Waits on Pfizer
Although Pfizer's license to the HCV program in markets outside of Asia remains in effect, major restructuring at the big pharma has raised questions about the future of the arrangement.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Exiqon Completes Assays for Tacere, Pfizer RNAi Drug Alliance
September 17, 2009 / Gene Silencing News - Benitec Closes Financing, Passes RAC Meeting as it Nears the Clinic
June 13, 2013 / Gene Silencing News - Benitec Looks to Outlicense IP While Avoiding Litigation Mistakes of Its Past
November 8, 2012 / Gene Silencing News - Tacere Considers Sale of Company as Pfizer Exercises Option to HCV Program
February 11, 2010 / Gene Silencing News - For Some RNAi Rx Shops, Industry Deals with Bigger Players are Par for the Course
August 20, 2009 / Gene Silencing News